125 related articles for article (PubMed ID: 25648135)
1. Bcl2 and Ki67 refine prognostication in luminal breast cancers.
Chen LY; Tsang JY; Ni YB; Chan SK; Chan KF; Zhang S; Tse GM
Breast Cancer Res Treat; 2015 Feb; 149(3):631-43. PubMed ID: 25648135
[TBL] [Abstract][Full Text] [Related]
2. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
4. ESPL1 is a candidate oncogene of luminal B breast cancers.
Finetti P; Guille A; Adelaide J; Birnbaum D; Chaffanet M; Bertucci F
Breast Cancer Res Treat; 2014 Aug; 147(1):51-9. PubMed ID: 25086634
[TBL] [Abstract][Full Text] [Related]
5. A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer.
Ali HR; Dawson SJ; Blows FM; Provenzano E; Leung S; Nielsen T; Pharoah PD; Caldas C
J Pathol; 2012 Jan; 226(1):97-107. PubMed ID: 21953021
[TBL] [Abstract][Full Text] [Related]
6. COX2 overexpression is a prognostic marker for Stage III breast cancer.
Kim HS; Moon HG; Han W; Yom CK; Kim WH; Kim JH; Noh DY
Breast Cancer Res Treat; 2012 Feb; 132(1):51-9. PubMed ID: 21533532
[TBL] [Abstract][Full Text] [Related]
7. Biological characteristics of luminal subtypes in pre- and postmenopausal estrogen receptor-positive and HER2-negative breast cancers.
Murase K; Yanai A; Saito M; Imamura M; Miyagawa Y; Takatsuka Y; Inoue N; Ito T; Hirota S; Sasa M; Katagiri T; Fujimoto Y; Hatada T; Ichii S; Nishizaki T; Tomita N; Miyoshi Y
Breast Cancer; 2014 Jan; 21(1):52-7. PubMed ID: 22359195
[TBL] [Abstract][Full Text] [Related]
8. Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index.
Callagy GM; Pharoah PD; Pinder SE; Hsu FD; Nielsen TO; Ragaz J; Ellis IO; Huntsman D; Caldas C
Clin Cancer Res; 2006 Apr; 12(8):2468-75. PubMed ID: 16638854
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of the Ki67 scoring categories in breast cancer subgroups.
Niikura N; Masuda S; Kumaki N; Xiaoyan T; Terada M; Terao M; Iwamoto T; Oshitanai R; Morioka T; Tuda B; Okamura T; Saito Y; Suzuki Y; Tokuda Y
Clin Breast Cancer; 2014 Oct; 14(5):323-329.e3. PubMed ID: 24492237
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
11. [Expression of Ki67 and clinicopathological features in breast cancer].
Wang B; Wang X; Wang J; Xuan L; Wang Z; Wang X; Gao J; Zhang H
Zhonghua Zhong Liu Za Zhi; 2014 Apr; 36(4):273-5. PubMed ID: 24989913
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
[TBL] [Abstract][Full Text] [Related]
13. Histological grade as an alternative to the Ki67 labeling index is only available for luminal-type breast cancers.
Hayashi S; Kitada M; Sato K; Matsuda Y; Ishibashi K; Oikawa K; Miyokawa N; Hirata S
Breast Cancer; 2014 Jan; 21(1):47-51. PubMed ID: 22467403
[TBL] [Abstract][Full Text] [Related]
14. CX3CL1 expression is associated with poor outcome in breast cancer patients.
Tsang JY; Ni YB; Chan SK; Shao MM; Kwok YK; Chan KW; Tan PH; Tse GM
Breast Cancer Res Treat; 2013 Aug; 140(3):495-504. PubMed ID: 23912959
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients.
Nagai MA; Gerhard R; Fregnani JH; Nonogaki S; Rierger RB; Netto MM; Soares FA
Breast Cancer Res Treat; 2011 Feb; 126(1):1-14. PubMed ID: 20369286
[TBL] [Abstract][Full Text] [Related]
16. BCL2L12: a promising molecular prognostic biomarker in breast cancer.
Tzovaras A; Kladi-Skandali A; Michaelidou K; Zografos GC; Missitzis I; Ardavanis A; Scorilas A
Clin Biochem; 2014 Dec; 47(18):257-62. PubMed ID: 25230343
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of CD24 and claudin-7 immunoexpression in ductal invasive breast cancer.
Bernardi MA; Logullo AF; Pasini FS; Nonogaki S; Blumke C; Soares FA; Brentani MM
Oncol Rep; 2012 Jan; 27(1):28-38. PubMed ID: 21956537
[TBL] [Abstract][Full Text] [Related]
18. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW
Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043
[TBL] [Abstract][Full Text] [Related]
19. Proposal for a modified grading system based on mitotic index and Bcl2 provides objective determination of clinical outcome for patients with breast cancer.
Abdel-Fatah TM; Powe DG; Ball G; Lopez-Garcia MA; Habashy HO; Green AR; Reis-Filho JS; Ellis IO
J Pathol; 2010 Dec; 222(4):388-99. PubMed ID: 20922713
[TBL] [Abstract][Full Text] [Related]
20. Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis.
Ingoldsby H; Webber M; Wall D; Scarrott C; Newell J; Callagy G
Breast; 2013 Oct; 22(5):879-86. PubMed ID: 23643806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
